Skip to contentL
Lexicon Pharmaceuticals, Inc.
L
LXRXLexicon Pharmaceuticals, Inc. Q2 2015 · 10-Q
Revenue$20.09M$20.09M+5,242.8% vs Q2 2014 Net Income-$38.11M-$38.11MN/M vs Q2 2014 EPS Diluted-$0.37-$0.37N/M vs Q2 2014 Operating Income-$37,021,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$47,891,000N/M Margins · derivedOperating margin-184.3%+6913.6 pt vs Q2 2014
Net margin-189.7%+7276.8 pt vs Q2 2014
ended Jun 30, 2016 · filed Aug 4, 2016 · 35 d after period end